COVID-19 and cardiovascular diseases

COVID-19 and cardiovascular diseases

First cases of new coronavirus infection were registered in December 2019. The COVID-19 outbreak was declared a global pandemic. COVID-19 is much more dangerous for people older than 65. It is well known that cardiovascular diseases are more affecting older patients as well. The potentially dangerou...

Full description

Bibliographic Details
Main Authors:	I. E. Chazova, O. I. Mironova
Format:	Article
Language:	Russian
Published:	"Consilium Medicum" Publishing house 2020-10-01
Series:	Терапевтический архив
Subjects:	covid-19 new coronavirus infection pandemic cardiovascular diseases arterial hypertension acute coronary syndrome myocarditis pulmonary embolism angiotensin-converting enzyme inhibitors angiotensin ii receptor blockers
Online Access:	https://ter-arkhiv.ru/0040-3660/article/viewFile/46843/31992

Similar Items

The problem of determining the efficiency of treatmentin the era of evidence-based medicine: international and domestic experience
by: S R Gilyarevsky
Published: (2014-06-01)

2019 novel-coronavirus: Cardiovascular insights about risk factors, myocardial injury, therapy and clinical implications
by: Luigi Cappannoli, et al.
Published: (2020-12-01)

TO THE 110-TH ANNIVERSARY OF RENIN FINDING. FIGHT OF TITANS: ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND SARTANS
by: L. N. Malay, et al.
Published: (2016-01-01)

Associations Between the Use of Renin–Angiotensin System Inhibitors and the Risks of Severe COVID-19 and Mortality in COVID-19 Patients With Hypertension: A Meta-Analysis of Observational Studies
by: Xiao-Ce Dai, et al.
Published: (2021-04-01)

Angiotensin-Converting Enzyme Inhibitor / Angiotensin II Receptor Blocker in COVID-19: a Double-edged Sword or a Myth
by: Kunal Bikram Shaha, et al.
Published: (2020-05-01)

Angiotensin-converting enzyme inhibitors or sartans in patients at high risk for cardiovascular events: a wrong question or an undesirable answer
by: S R Gilyarevsky, et al.
Published: (2013-03-01)

Association between chronic ACE inhibitor exposure and decreased odds of severe disease in patients with COVID-19
by: Naci Şenkal, et al.
Published: (2020-07-01)

Angiotensin II Promotes SARS-CoV-2 Infection via Upregulation of ACE2 in Human Bronchial Cells
by: Brini, M., et al.
Published: (2022)

Impact of drug therapy on the risk of death in patients with coronary heart disease (according to the data of registry of cardiovascular diseases, RECVASA)
by: K. G Pereverzeva, et al.
Published: (2017-09-01)

COVID-19 morbidity and mortality associated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers use among 14,129 patients with hypertension from a US integrated healthcare system
by: Jaejin An, et al.
Published: (2021-06-01)

Candesartan in nephrological practice
by: Ya.A. Dombrovskyi, et al.
Published: (2014-02-01)

Clinical outcome of renin-angiotensin-aldosterone system blockers in treatment of hypertensive patients with COVID-19: a systematic review and meta-analysis
by: Andrea Laurentius, et al.
Published: (2021-02-01)

Resistance to antihypertensive drugs targeting Renin-Angiotensin-Aldosterone-System in cancer patients: a case series
by: Mishita Goel, et al.
Published: (2020-08-01)

ANGIOTENSIN RECEPTOR BLOCKERS WITH PLEIOTROPIC PROPERTIES: A NEW STANDARD IN CARDIOVASCULAR RISK MANAGEMENT AND TREATMENT OF HYPERTENSION
by: V. I. Podzolkov, et al.
Published: (2017-07-01)

Hypertension, renin-angiotensin-aldosterone-system-blocking agents, and COVID-19
by: Si-Hyuck Kang, et al.
Published: (2021-06-01)

Acquisition of renin-angiotensin-aldosterone system inhibitors for the treatment of cardiovascular diseases in regions of the Far Eastern Federal District
by: M. S. Soboleva, et al.
Published: (2020-04-01)

Renin-angiotensin system modulators and other risk factors in COVID-19 patients with hypertension: a Korean perspective
by: Hee-Sung Kim, et al.
Published: (2021-02-01)

Inhibition of Angiotensin Converting Enzyme Impairs Anti-staphylococcal Immune Function in a Preclinical Model of Implant Infection
by: Rishi Trikha, et al.
Published: (2020-09-01)

Hyponatremia Induced by Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers-A Pilot Study
by: S Bhuvaneshwari, et al.
Published: (2018-07-01)

A high sodium intake reduces antiproteinuric response to renin–angiotensin–aldosterone system blockade in kidney transplant recipients
by: Elena Monfá, et al.
Published: (2016-09-01)

Meta-analysis of the association between angiotensin pathway inhibitors and COVID-19 severity and mortality
by: Malindu E. Fernando, et al.
Published: (2021-09-01)

Management of diabetic hypertensives
by: Jai Ganesh, et al.
Published: (2011-01-01)

Inhibitors of the renin-angiotensin system ameliorates clinical and pathological aspects of experimentally induced nephrotoxic serum nephritis
by: M. E. Ougaard, et al.
Published: (2018-10-01)

A systematic review and meta‐analysis of the use of renin‐angiotensin system drugs and COVID‐19 clinical outcomes: What is the evidence so far?
by: Amanj Kurdi, et al.
Published: (2020-12-01)

Angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers for COVID-19: A living systematic review of randomized clinical trials
by: Nicolás Meza, et al.
Published: (2021-03-01)

Association of Hypertension with All-Cause Mortality among Hospitalized Patients with COVID-19
by: Enrique Rodilla, et al.
Published: (2020-09-01)

Effect of Different Classes of Antihypertensive Drugs on Endothelial Function and Inflammation
by: Isabella Viana Gomes Silva, et al.
Published: (2019-07-01)

Treatment of hypertension during the COVID-19 pandemic: questions about the blockade of the renin-angiotensin-aldosterone system
by: S. G. Kanorskiy
Published: (2021-04-01)

Consequences of continuing renin angiotensin aldosterone system antagonists in the preoperative period: a systematic review and meta-analysis
by: Qiong Ling, et al.
Published: (2018-02-01)

Effects of renin-angiotensin system blockers on the risk and outcomes of severe acute respiratory syndrome coronavirus 2 infection in patients with hypertension
by: Jinwoo Lee, et al.
Published: (2021-03-01)

The use of angiotensin-converting enzyme inhibitors vs. angiotensin receptor blockers and cognitive decline in Alzheimer’s disease: the importance of blood-brain barrier penetration and APOE ε4 carrier status
by: Michael Ouk, et al.
Published: (2021-02-01)

Effect of an angiotensin-converting-enzyme inhibitor on the plasma concentration of cytokines and vasoactive molecules in patients with coronary heart disease and hypertension
by: A A Khadartsev, et al.
Published: (2017-12-01)

Angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARBs) may be safe for COVID-19 patients
by: Wenjun Wang, et al.
Published: (2021-01-01)

Reply to Siniorakis et al., “COVID-19 Interference with Renin-Angiotensin System in the Context of Heart Failure”
by: David S. Fedson, et al.
Published: (2020-05-01)

Angiotensin II Receptor Blockers but Not Angiotensin-Converting Enzyme Inhibitors Are Associated With a Reduced Risk of Acute Kidney Injury After Major Surgery
by: Shao-Yu Yang, et al.
Published: (2021-04-01)

Treatment of hypertension in children and adolescents
by: I. V. Leontyeva
Published: (2019-03-01)

Relating angiotensin‐converting enzyme inhibitors or angiotensin receptor blockers with incidence or mortality of COVID‐19
by: Martin C.S. Wong, et al.
Published: (2020-10-01)

Stopping renin-angiotensin system blockers after acute kidney injury and risk of adverse outcomes: parallel population-based cohort studies in English and Swedish routine care
by: Patrick Bidulka, et al.
Published: (2020-07-01)

Resistive index as a predictor of acute kidney injury caused by an angiotensin converting enzyme inhibitor or angiotensin II receptor blocker in chronic kidney disease patients
by: Eun Seok Kim, et al.
Published: (2013-12-01)

Association of ACEi/ARB Use and Clinical Outcomes of COVID-19 Patients With Hypertension
by: Jing Ma, et al.
Published: (2021-05-01)